STAAR Surgical (STAA) director Wei Jiang RSU award fully vests

Rhea-AI Filing Summary

STAAR Surgical director Wei Jiang reported the vesting and conversion of restricted stock units into common shares. On January 12, 2026, 20,967 restricted stock units granted on May 12, 2025 vested and were converted into 20,967 shares of STAAR Surgical common stock at an exercise price of $0 per share. These units were the final third of an award that vested in three equal installments on August 12, 2025, November 12, 2025, and January 12, 2026. Following this transaction, Jiang directly beneficially owned 66,444 shares of STAAR Surgical common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jiang Wei

(Last) (First) (Middle)

25510 COMMERCENTRE DRIVE

(Street)

LAKE FOREST CA 92630

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STAAR SURGICAL CO [ STAA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/12/2026		M		20,967(1)	A	$0	66,444	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(2)	01/12/2026		M			20,967	(1)	(1)	Common Stock	20,967	$0	0	D

Explanation of Responses:

1. Reflects restricted stock units (RSUs) granted to the Reporting Person on May 12, 2025. These RSUs vested as to 1/3 of the shares subject to the award (20,967 shares) on August 12, 2025, 1/3 (20,967 shares) on November 12, 2025, and 1/3 (20,967 shares) on January 12, 2026.

2. Each RSU represents the right to receive one share of the Corporation's common stock upon vesting.

Remarks:

As disclosed in the Corporation's Current Report on Form 8-K filed on April 24, 2025, the Corporation entered into a consulting agreement with Mr. Jiang to serve as a special strategic advisor to the Corporation's Asia Pacific business through the end of fiscal 2025, in the temporary role of Chief of APAC Strategy. This Form 4 reflects the vesting of RSUs granted to Mr. Jiang in connection with such service.

	/s/ Nathaniel Sisitsky as attorney-in-fact for Wei Jiang	01/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did STAAR Surgical (STAA) disclose in this Form 4 for Wei Jiang?

The filing reports that director Wei Jiang had 20,967 restricted stock units vest and convert into 20,967 shares of STAAR Surgical common stock on January 12, 2026 at an exercise price of $0 per share.

How many STAAR Surgical shares does Wei Jiang own after the January 12, 2026 transaction?

After the reported transaction, Wei Jiang beneficially owned 66,444 shares of STAAR Surgical common stock directly.

What was the source and vesting schedule of Wei Jiangs STAAR Surgical RSUs?

The restricted stock units were granted on May 12, 2025 and vested in three equal installments of 20,967 units each on August 12, 2025, November 12, 2025, and January 12, 2026.

What does each restricted stock unit represent in this STAAR Surgical Form 4?

Each restricted stock unit (RSU) represents the right to receive one share of STAAR Surgical common stock upon vesting.

Did Wei Jiang sell any STAAR Surgical shares in this Form 4 transaction?

The reported transaction code is M, indicating the exercise/vesting of derivative securities into common stock. The Form 4 shows RSUs converting into common shares at $0, with no separate sale transaction disclosed in the excerpt.

What role does Wei Jiang have at STAAR Surgical?

Wei Jiang is reported as a director of STAAR Surgical. The remarks note that the RSUs were granted in connection with his service as a special strategic advisor to the Asia Pacific business through the end of fiscal 2025.